Recombinant Human UDP-glucuronosyltransferase 1A9 (UGT1A9)

1. Icaritin was subjected to significant glucuronidation, wherein UGT1A3, 1A7, 1A8, 1A9 and 2B7 were main contributing enzymes. PMID: 28443723
2. Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity PMID: 27857056
3. The findings of the study highlighted correlation between UGT1A9 -440C/T gene polymorphisms and positive propofol efficacy in patients undergoing painless induced pregnancy termination procedures. PMID: 28899924
4. A significantly higher number of UGT1A9 polymorphisms was found in the group that did not respond to Mycophenolic acid treatment. PMID: 27549213
5. None of the patients with Regorafenib-induced severe toxic hepatitis had CYP3A4 gene mutations. Similar polymorphisms in UGT1A9 gene promoter region were found in both patients who presented acute hepatitis. PMID: 27500989
6. No association between the UGT1A9 c.98T>C polymorphism and mycophenolic acid plasma levels were found in renal transplant patients. PMID: 28613375
7. UGT1A1, UGT1A6, and UGT1A9 were the chief contributors to the regioselective glucuronidation of diosmetin and chrysoeriol in the liver. PMID: 27832172
8. polymorphisms c.98T>C in the UGT1A9 and c.1075A>C in the CYP2C9 genes did not affect the pharmacokinetic profile of propofol PMID: 27826892
9. Carriers of T-275A and C-2152T single-nucleotide polymorphisms of the UGT1A9 gene promoter region show a greater incidence of death from digestive system cancer after kidney transplantation. PMID: 27932114
10. demonstrated the effects of UGT1A9 genetic polymorphisms on MHD plasma concentrations and OXC therapeutic efficacy. Through MHD monitoring, we can predict OXC therapeutic efficacy, which may be useful for the personalization of OXC therapy in epileptic patients PMID: 27900402
11. Dimerization changed the chemical regioselectivity, substrate-binding affinity, and enzymatic activity of UGT1A1 and UGT1A9 in glucuronidation of quercetin. PMID: 27025983
12. UGT1A9 contributes to the in-vitro glucuronidation of arctigenin in liver microsomes. PMID: 26407805
13. Suggest that the enzymatic properties of UGT1A9 are considerably different between humans and cynomolgus monkeys, although humUGT1A9 and monUGT1A9 were highly conserved at the amino acid level. PMID: 24470170
14. We observed statistically significant associations between SNP and Drug-induced liver injury at both allele and genotype levels of of UGT1A9 promoter PMID: 25446781
15. in tumor liver microsomes from HCC patients, either V(max) (maximum reaction rate, R(max) for UGT1A1) or clearance rates (V(max)/K(m), Clint) of UGT1A, UGT1A1, UGT1A4, UGT1A9 and UGT2B7 were lower than those in the adjacent normal liver microsomes PMID: 26010150
16. Significantly lower estimated glomerular filtration rate of the renal allograft in UGT1A9 c.98C carriers did not translate into decreased allograft survival. PMID: 25380893
17. Data shows that UGT1A9*22 allele was significantly less frequent in the Uzbek population compared to the Japanese. PMID: 24453052
18. UGT1A9 is the major isoform responsible for the glucuronidations of fraxetin in liver microsomes. PMID: 24025985
19. In HeLa cells overexpressing UGT1A9 there was an increase in catalysis and production of luteolin glucuronides. PMID: 24092055
20. the UGT1A9 proximal promoter was assumed to change into the non-active form from the original sequence, and this might be one of the reasons for the tissue-specific expression of UGT1A9. PMID: 23842475
21. UGT1A9 is a major contributor for (R) and (S) glucuronidation in the human liver and kidney. PMID: 23527766
22. Alleles UGT1A9*4 and UGT1A9*5 were not present in any of the subjects of Polish population. PMID: 23184343
23. determined the kinetics of efflux of 13 flavonoid glucuronides using the newly developed HeLa-UGT1A9 cells and correlated them with kinetic parameters derived using expressed UGT1A9 PMID: 23402418
24. Data suggest that the substrate specificity of UGT1A9 includes the antiviral drug arbidol; UGT1A9 appears to be the major UGT isoform involved in the formation of arbidol glucuronides by liver microsomes. PMID: 23488780
25. UGT1A9 and 2B7 are the main enzymes involved in ethanol glucuronidation. In addition, our results suggest that cannabinol and cannabidiol could significantly alter ethanol glucuronidation. PMID: 23230132
26. none of the SNPs in UGT1A9 were present in our study population PMID: 23700788
27. genetic association studies in pediatric population in United States: Data suggest that combined SNPs in UGT1A9, UGT2B7, and MRP2 are important in pharmacokinetics/biotransformation of prodrug mycophenolate mofetil in kidney transplant recipients. PMID: 23131697
28. In Parkinson's disease patients UDP-glucuronosyltransferase 1A9 genotypes are associated with adverse reactions to to catechol-O-methyltransferase inhibitors PMID: 22527346
29. increased cumulated drug exposure and UGT1A9 polymorphism (rs17868320) identified patients at high risk for early sorafenib-induced severe toxicity PMID: 22912756
30. Expression of UGT1A9 correlated with age only in children younger than 1 year (Spearman r = 0.70). PMID: 22492655
31. Study indicates that genotype status of UGT1A1, UGT1A9, and ABCC2 and serum bilirubin concentration increases reflect abnormally high AUC in patients treated with sorafenib. PMID: 22307138
32. Report molecular models that can predict phenol substrate selectivity and in vitro clearance of UGT1A9. PMID: 22302521
33. Investigation of morinidazole glucuronidation using human liver microsomes (HLMs) and 12 recombinant UDP glucuronosyltransferases (UGTs) indicated that this biotransformation was mainly catalyzed by UGT1A9. PMID: 22184458
34. Data suggest that darexaban glucuronidation in liver microsomes is mainly catalyzed by UGT1A9; studies include kinetics of recombinant UGT proteins, liver microsomes, and jejunal microsomes (and UGT isoform-specific inhibitors/substrates). PMID: 22031623
35. transplanted kidney function may be affected in patients carrying UGT1A9 98C allele and receiving mycophenolate mophetil PMID: 22210424
36. The presence of BSA during the glucuronidation reaction leads to a large increase in the V(max) value of UGT1A9, in addition to lowering its K(m) value. PMID: 21856742
37. A significantly stereoselective difference on the glucuronidation of rac-FPF was seen between the two variants compared with the wild type of UGT1A9. PMID: 21856293
38. In a study of Japanese renal transplant recipients, there are no significant differences in the area under the plasma concentration-time curve ratio of mycophenolic acid glucuronide/MPA between UGT1A9 I399C/T genotypes. PMID: 18695635
39. analysis of stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9 PMID: 19644937
40. Further mutagenesis and activity assays suggested that Phe117 of UGT1A9 participates in 1-naphthol binding PMID: 20089735
41. Data point to UGT1A9 as main UGT isoform in liver microsomes metabolizing psilocin (a hallucinogenic indole alkaloid); kinetic studies are included. PMID: 20007669
42. N-glycosylation has an important role in the folding of UGT1A9. PMID: 19951703
43. In this study, we sequenced the promoter and exon 1 regions of the UGT1A9 gene in 93 Thai individuals and identified 7 genetic polymorphisms PMID: 19881262
44. Carriers of single nucleotide polymorphisms in this protein's promotor region show a greater incidence of gastrointestinal side effects and lower exposure to mycophenolic acid. PMID: 19715905
45. sequence of the cDNA segment cloned, 1666 bp in length. The recombinant constructed, pREP9-UGT1A9, contains the entire coding region, along with 18 bp of the 5' and 55 bp of the 3' untranslated region of theUGT1A9 cDNA. PMID: 11854913
46. 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene PMID: 12582161
47. a significant role for UGT1A9 and 2B7 in the catalysis of almokalant glucuronidation PMID: 14660172
48. mutant allele with one base insertion in the promoter region of the UGT1A9 gene would alter the level of enzyme expression and the metabolism of those drugs that are substrates of UGT1A9 PMID: 15115919
49. Study provides preliminary evidence that genetic factors, especially in hepatic UGT1A9, may contribute to the variability of mycophenolic acid pharmacokinetics observed in transplant patients. PMID: 15258099
50. stereoselectivity for etodolac PMID: 15370961

Show More

Hide All

HGNC: 12541

OMIM: 191740

KEGG: hsa:54600

STRING: 9606.ENSP00000346768

UniGene: Hs.554822